Literature DB >> 22821230

Does conservative management really benefit patients with OAB?

Philip E V Van Kerrebroeck1.   

Abstract

The benefit that patients with overactive bladder (OAB) experience with conservative management is an important aspect in the evaluation of this therapy. The first-line options include behavioral interventions, and several techniques are available. Clinical research indicates amelioration of individual symptoms with these techniques, but few studies have shown a positive effect on health-related quality-of-life parameters. After failure of behavioral therapy or in combination with a training program, pharmacological therapy with anticholinergics is the next step. Extensive clinical research into different pharmacological compounds has shown significant effects on the symptomatic elements of OAB. The clinical relevance and the effects on quality-of-life parameters with pharmacological therapy have also been evaluated and show a significant effect on specific aspects. Recently, clinical research in conservative management of patients with OAB has focused more on evaluating patients' perceptions of their condition and the effects of treatment with patient-reported outcome instruments. Future studies should include these tools in the evaluation of any therapy in OAB.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22821230     DOI: 10.1007/s11934-012-0262-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  70 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

2.  Adherence to a behavioral program to prevent incontinence.

Authors:  Sandra H Hines; Julia S Seng; Kassandra L Messer; T E Raghunathan; Ananias C Diokno; Carolyn M Sampselle
Journal:  West J Nurs Res       Date:  2007-02       Impact factor: 1.967

3.  Overactive bladder inhibition in response to pelvic floor muscle exercises.

Authors:  Ahmed Shafik; Ismail A Shafik
Journal:  World J Urol       Date:  2003-04-04       Impact factor: 4.226

Review 4.  Reviewing the ICS 2002 terminology report: The ongoing debate.

Authors:  Paul Abrams; Walter Artibani; Linda Cardozo; Roger Dmochowski; Philip van Kerrebroeck; Peter Sand
Journal:  Neurourol Urodyn       Date:  2006-04-12       Impact factor: 2.696

Review 5.  Tolterodine use for symptoms of overactive bladder.

Authors:  J M Ruscin; N E Morgenstern
Journal:  Ann Pharmacother       Date:  1999-10       Impact factor: 3.154

6.  Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

Authors:  D M Gleason; J Susset; C White; D R Munoz; P K Sand
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

7.  Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group.

Authors:  J F Wyman; J A Fantl; D K McClish; R C Bump
Journal:  Am J Obstet Gynecol       Date:  1998-10       Impact factor: 8.661

8.  Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.

Authors:  Kathryn L Burgio; Stephen R Kraus; Shawn Menefee; Diane Borello-France; Marlene Corton; Harry W Johnson; Veronica Mallett; Peggy Norton; Mary P FitzGerald; Kimberly J Dandreo; Holly E Richter; Thomas Rozanski; Michael Albo; Halina M Zyczynski; Gary E Lemack; Toby C Chai; Salil Khandwala; Jan Baker; Linda Brubaker; Anne M Stoddard; Patricia S Goode; Betsy Nielsen-Omeis; Charles W Nager; Kimberly Kenton; Sharon L Tennstedt; John W Kusek; T Debuene Chang; Leroy M Nyberg; William Steers
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

9.  Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Authors:  Christopher R Chapple; Philip E Van Kerrebroeck; Klaus-Peter Jünemann; Joseph T Wang; Marina Brodsky
Journal:  BJU Int       Date:  2008-07-21       Impact factor: 5.588

Review 10.  Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.

Authors:  F Haab; L Stewart; P Dwyer
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

View more
  2 in total

Review 1.  Physical, Complementary, and Alternative Medicine in the Treatment of Pelvic Floor Disorders.

Authors:  Alex Arnouk; Elise De; Alexandra Rehfuss; Carin Cappadocia; Samantha Dickson; Fei Lian
Journal:  Curr Urol Rep       Date:  2017-06       Impact factor: 3.092

2.  Short-term Effects of a Systematized Bladder Training Program for Idiopathic Overactive Bladder: A Prospective Study.

Authors:  Hahn-Ey Lee; Sung Yong Cho; Sangim Lee; Myong Kim; Seung-June Oh
Journal:  Int Neurourol J       Date:  2013-03-31       Impact factor: 2.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.